Administration of pure follicle-stimulating hormone during gonadotropin-releasing hormone agonist therapy in patients with clomiphene-resistant polycystic ovarian disease: Hormonal evaluations and clinical perspectives

Valentino Remorgida, Pier Luigi Venturini, Paola Anserini, Paolo Lanera, Luigi De Cecco

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Nine women with chronic anovulation caused by polycystic ovarian disease, which was unresponsive to clomiphene citrate therapy, were given a gonadotropin-releasing hormone agonist (buserelin) to induce pituitary desensitization. After 4 weeks induction of ovulation was attempted with a step-up administration of urinary follicle-stimulating hormone. Buserelin treatment was discontinued only in the presence of a positive pregnancy test result. Different responses were observed between the first and subsequent cycles. Whereas estradiol production and follicular growth were closely correlated in the first attempt, we recorded a dissociation between these two parameters of ovarian response during subsequent stimulations. Four clinical pregnancies occurred in these nine patients, and there was one abortion. This therapeutic approach can be successfully used to induce ovulation; however, prolonging pituitary suppression between treatment cycles changes the type of ovarian response and is not followed by better results.

Original languageEnglish
Pages (from-to)108-113
Number of pages6
JournalAmerican Journal of Obstetrics and Gynecology
Volume160
Issue number1
DOIs
Publication statusPublished - 1989

Fingerprint

Ovarian Diseases
Clomiphene
Follicle Stimulating Hormone
Gonadotropin-Releasing Hormone
Buserelin
Anovulation
Pregnancy Tests
Ovulation Induction
Therapeutics
Menstrual Cycle
Ovulation
Estradiol
Pregnancy
Growth

Keywords

  • follicle-stimulating hormone therapeutic use
  • gonadotropin-releasing hormone analogs
  • ovulation induction
  • Polycystic ovarian disease

ASJC Scopus subject areas

  • Medicine(all)
  • Obstetrics and Gynaecology

Cite this

Administration of pure follicle-stimulating hormone during gonadotropin-releasing hormone agonist therapy in patients with clomiphene-resistant polycystic ovarian disease : Hormonal evaluations and clinical perspectives. / Remorgida, Valentino; Venturini, Pier Luigi; Anserini, Paola; Lanera, Paolo; De Cecco, Luigi.

In: American Journal of Obstetrics and Gynecology, Vol. 160, No. 1, 1989, p. 108-113.

Research output: Contribution to journalArticle

@article{33752f018d8349a09468361ed514cc1b,
title = "Administration of pure follicle-stimulating hormone during gonadotropin-releasing hormone agonist therapy in patients with clomiphene-resistant polycystic ovarian disease: Hormonal evaluations and clinical perspectives",
abstract = "Nine women with chronic anovulation caused by polycystic ovarian disease, which was unresponsive to clomiphene citrate therapy, were given a gonadotropin-releasing hormone agonist (buserelin) to induce pituitary desensitization. After 4 weeks induction of ovulation was attempted with a step-up administration of urinary follicle-stimulating hormone. Buserelin treatment was discontinued only in the presence of a positive pregnancy test result. Different responses were observed between the first and subsequent cycles. Whereas estradiol production and follicular growth were closely correlated in the first attempt, we recorded a dissociation between these two parameters of ovarian response during subsequent stimulations. Four clinical pregnancies occurred in these nine patients, and there was one abortion. This therapeutic approach can be successfully used to induce ovulation; however, prolonging pituitary suppression between treatment cycles changes the type of ovarian response and is not followed by better results.",
keywords = "follicle-stimulating hormone therapeutic use, gonadotropin-releasing hormone analogs, ovulation induction, Polycystic ovarian disease",
author = "Valentino Remorgida and Venturini, {Pier Luigi} and Paola Anserini and Paolo Lanera and {De Cecco}, Luigi",
year = "1989",
doi = "10.1016/0002-9378(89)90099-9",
language = "English",
volume = "160",
pages = "108--113",
journal = "American Journal of Obstetrics and Gynecology",
issn = "0002-9378",
publisher = "Mosby Inc.",
number = "1",

}

TY - JOUR

T1 - Administration of pure follicle-stimulating hormone during gonadotropin-releasing hormone agonist therapy in patients with clomiphene-resistant polycystic ovarian disease

T2 - Hormonal evaluations and clinical perspectives

AU - Remorgida, Valentino

AU - Venturini, Pier Luigi

AU - Anserini, Paola

AU - Lanera, Paolo

AU - De Cecco, Luigi

PY - 1989

Y1 - 1989

N2 - Nine women with chronic anovulation caused by polycystic ovarian disease, which was unresponsive to clomiphene citrate therapy, were given a gonadotropin-releasing hormone agonist (buserelin) to induce pituitary desensitization. After 4 weeks induction of ovulation was attempted with a step-up administration of urinary follicle-stimulating hormone. Buserelin treatment was discontinued only in the presence of a positive pregnancy test result. Different responses were observed between the first and subsequent cycles. Whereas estradiol production and follicular growth were closely correlated in the first attempt, we recorded a dissociation between these two parameters of ovarian response during subsequent stimulations. Four clinical pregnancies occurred in these nine patients, and there was one abortion. This therapeutic approach can be successfully used to induce ovulation; however, prolonging pituitary suppression between treatment cycles changes the type of ovarian response and is not followed by better results.

AB - Nine women with chronic anovulation caused by polycystic ovarian disease, which was unresponsive to clomiphene citrate therapy, were given a gonadotropin-releasing hormone agonist (buserelin) to induce pituitary desensitization. After 4 weeks induction of ovulation was attempted with a step-up administration of urinary follicle-stimulating hormone. Buserelin treatment was discontinued only in the presence of a positive pregnancy test result. Different responses were observed between the first and subsequent cycles. Whereas estradiol production and follicular growth were closely correlated in the first attempt, we recorded a dissociation between these two parameters of ovarian response during subsequent stimulations. Four clinical pregnancies occurred in these nine patients, and there was one abortion. This therapeutic approach can be successfully used to induce ovulation; however, prolonging pituitary suppression between treatment cycles changes the type of ovarian response and is not followed by better results.

KW - follicle-stimulating hormone therapeutic use

KW - gonadotropin-releasing hormone analogs

KW - ovulation induction

KW - Polycystic ovarian disease

UR - http://www.scopus.com/inward/record.url?scp=0024493158&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024493158&partnerID=8YFLogxK

U2 - 10.1016/0002-9378(89)90099-9

DO - 10.1016/0002-9378(89)90099-9

M3 - Article

C2 - 2492145

AN - SCOPUS:0024493158

VL - 160

SP - 108

EP - 113

JO - American Journal of Obstetrics and Gynecology

JF - American Journal of Obstetrics and Gynecology

SN - 0002-9378

IS - 1

ER -